The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.